Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data.

Flaig, Thomas W.; Potluri, Ravi; Ng, Yvette; Todd, Mary B.; Mehra, Maneesha

doi:10.1200/jco.2014.32.15_suppl.e16010

Cited by 10 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12,13 Currently, there is a trend to use these novel hormonal therapies before chemotherapy, because of better tolerability. 14 Elucidating an appropriate treatment sequence of these therapies is important for maximizing clinical benefit of CRPC patients. Therefore, we carried out a retrospective multi-institutional study in Japan (Kyoto) and the USA (Baltimore) to examine the potential differences in clinical outcomes between the treatment sequences of ABI-to-ENZA and ENZA-to-ABI.…”

Section: Introductionmentioning

confidence: 99%

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

et al. 2017

View full text Add to dashboard Cite

The abiraterone-to-enzalutamide sequence might have more favorable efficacy in terms of combined prostate-specific antigen progression-free survival than the enzalutamide-to-abiraterone sequence, although no differences in overall survival were observed. This could possibly be attributable to longer prostate-specific antigen progression-free survival with second-line enzalutamide compared with abiraterone.

show abstract

Section: Introductionmentioning

confidence: 99%

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

et al. 2017

View full text Add to dashboard Cite

show abstract

“…As previously reported, second line AR-targeted agents were the most commonly used treatment modality in this cohort. 22 When The rPFS of single-agent radium-223 or sipuleucel-T was numerically shorter when compared with the registration trials ALSYMPCA and IMPACT, respectively. 19,21 The reasons for these results were somewhat intriguing.…”

Section: Discussionmentioning

confidence: 99%

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo‐hormonal therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Bei Patienten nach Docetaxel-haltiger Chemotherapie wurde in der Abirateron/Prednison (AP)-Gruppe ein signifikant verlängertes Gesamtüberleben (15,8 Monate) im Vergleich zur Placebogruppe (Prednison-Monotherapie; 11,2 Monaten) beobachtet [37]. Auch hinsichtlich der sekundären Endpunkte Zeit bis zum PSAProgress, progressionsfreies Überleben und PSA-Rückgang > 30 % zeigte sich ein signifikanter Vorteil für AP.…”

Section: Gezielte Therapie Des Ar-signaltransduktionswegsunclassified

“…Gemäß Zulassungsstatus können beim mCRPC derzeit Abirateron oder Docetaxel als Erstlinientherapien eingesetzt werden, die Zulassung von Enzalutamid wird erwartet. Mit der Verfüg-barkeit der neuen Substanzen geht der Einsatz von Docetaxel schon jetzt im Praxisalltag stetig zurück [8]. Abirateron ist aufgrund des günstigen Nebenwirkungsspektrums für Patienten ohne oder mit nur geringer klinischer Symptomatik und fehlender viszeraler Metastasierung geeignet.…”

Section: Therapiesequenzen Des Metastasierten Kastrationsresistenten unclassified

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom

Stroelin

Bokemeyer

et al. 2014

Dtsch med Wochenschr

View full text Add to dashboard Cite

Metastasized castration-resistant prostate cancer (mCRPC) is defined by disease progression despite androgen depletion therapy (ADT). While until recently a life-prolonging effect could only be demonstrated for the taxane docetaxel, various alternative therapeutic options based on different mechanisms of action are available today: CYP17-inhibitor abiraterone and antiandrogen enzalutamide target the androgen receptor-signaling pathway, which maintains a crucial role in mCRPC. Cabazitxel - a semisynthetic taxane derivate - is the only second line chemotherapy, which results in a prolongation of overall survival to date. Alpha emitter Radium-223 has the ability to mimic calcium and target bone metastases. Thus, it is a reasonable therapeutic alternative for patients suffering from symptomatic bone metastases. In 2013, Sipuleucel-T was the first immunotherapy approved for CRPC in Europe. In this review we introduce the different therapeutic options to the reader, reflect the possible therapeutic sequences and give a perspective on novel pipeline medications.

show abstract

Treatment evolution for metastatic castration-resistant prostate cancer (mCRPC) with recent introduction of new oral agents: Retrospective analysis of real world data.

Cited by 10 publications

References 0 publications

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy‐naïve castration‐resistant prostate cancer: The Kyoto‐Baltimore collaboration

Treatment selection for men with metastatic prostate cancer who progress on upfront chemo‐hormonal therapy

Aktuelle Therapiekonzepte bei kastrationsresistenten Prostatakarzinom

Contact Info

Product

Resources

About